KRAS and non-small cell lung carcinoma: Using the sequential treatment scheme (Figure 2A), KRAS-G12C-mutated NSCLC cell lines (SW1573 and H23) were seeded and after 24 hours were treated with a combination of chemotherapeutics, including gemcitabine (IC50 H23: 3.3nM-SW1573: 4nM) plus carboplatin (IC50 H23: 30μM-SW1573: 64μM) (Gem+Carbo), pemetrexed (IC50 H23: 2.3nM-SW1573: 37μM) plus carboplatin (Peme+Carbo), and paclitaxel (IC50 H23: 134μM-SW1573: 245μM) plus carboplatin (Pacli+Carbo), for 48 hours at their IC50.